Dr. Reddy’s Versavo® is available in strengths of 100mg and 400mg single use vials.
Commenting on the launch, MV Ramana, CEO - India and Emerging Markets, Dr. Reddy’s Laboratories, said, “We regard the good health of our patients as our responsibility and are committed to ensure that they always have access to the medicines they need. The launch of Versavo® is another step in that journey and helps strengthen our Oncology portfolio.”
Dr. Raymond De Vré, Global Head, Biologics, Dr. Reddy’s Laboratories added, “Versavo® will help improve access to high quality therapy at an affordable cost, addressing the needs of patients with different cancers in India.”
Avastin® and its biosimilars had India sales of approximately INR 223 Crore MAT for the most recent twelve months ending in December 2018, according to Ipsos*.
Dr. Reddy’s now has six biosimilar products commercialized in India and various emerging markets and an active development pipeline of several biosimilar products in the oncology and immunology space.
*Ipsos India Tandem Oncology Monitor 2018
That the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and,
There are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.
The company assumes no obligation to update any information contained herein.